Valina L. Dawson

TL;DR: It is demonstrated that mutant PINK1 p.I368N can not be stabilized on the OMM upon mitochondrial stress and due to conformational changes in the active site does not exert kinase activity towards Ub, highlighting potential strategies for future drug development.

TL;DR: These data demonstrate that FK506 provides robust neuroprotection against transient focal cerebral ischemia in the rat, and the mechanism of protection in vivo is not through attenuation of ischemic-evoked NO production during MCAO and early reperfusion.

TL;DR: Conditional transgenic mice that selectively express human R1441C LRRK2 in dopaminergic neurons from the endogenous murine ROSA26 promoter reveal altered dopamine neuronal morphology with advancing age, and provide a useful tool for exploring the pathogenic mechanisms underlying the R14 41C L RRK2 mutation in PD.

TL;DR: It is the first time to observe nanozyme can block prion-like spreading, which provides a proof of concept for nanozyme therapy, and it is anticipated that the biomedical application of nanozyme against prional spreading could be optimized and considered to be developed as a therapeutic strategy against Parkinson’s disease, Alzheimer's disease, and other prions-like proteinopathies.

TL;DR: Parkinson's disease (PD) is a progressive neurodegenerative disorder resulting from the death of dopamine neurons in the substantia nigra pars compacta as discussed by the authors, which can cause monogenetic PD when mutated.